Clinical trial of a new antigonadotropic substance, 2,6-cis-diphenylhexamethylcyclotetrasiloxane, in cancer of the prostate. A pilot study.

An organic siloxane compound, 2,6-cis-diphenylhexamethylcyclotetrasiloxane, (Cisobitan) has been shown to possess antigonadotropic properties. In this study it has been tried in prostatic cancer. 9 patients received the drug in the dose of 4-5 mg/kg body weight. General condition and subjective response, cytologic changes and semiquantitative scintigraphic changes of metastases were recorded, as well as common laboratory data. In this limited trial, Cisobitan was not adequate for tumour palliation. In a few instances subsequent oestrogen treatment was more effective. No side effects of Cisobitan were noted for periods up to 6 months. Further studies may be of value, perhaps using a higher dose.

Priapism: surgical or medical treatment?

Two cases of priapism treated with fibrinolysin (streptokinase) are presented. Comparisons are made between medical and surgical treatment in the literature. It is concluded that fibrinolysin may be useful in some cases of early priapism, but should be chosen only after serious consideration of the circumstance that its use precludes early surgery.